Nurix Therapeutics (NRIX) Competitors $9.78 -0.36 (-3.55%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$9.77 -0.01 (-0.10%) As of 05/21/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRIX vs. ALVO, SRRK, MRUS, ACAD, CPRX, MOR, PTGX, MTSR, XENE, and MLTXShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Alvotech (ALVO), Scholar Rock (SRRK), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), Protagonist Therapeutics (PTGX), Metsera (MTSR), Xenon Pharmaceuticals (XENE), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Nurix Therapeutics vs. Alvotech Scholar Rock Merus ACADIA Pharmaceuticals Catalyst Pharmaceuticals MorphoSys Protagonist Therapeutics Metsera Xenon Pharmaceuticals MoonLake Immunotherapeutics Alvotech (NASDAQ:ALVO) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Is ALVO or NRIX more profitable? Alvotech has a net margin of -123.47% compared to Nurix Therapeutics' net margin of -354.85%. Alvotech's return on equity of 0.00% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alvotech-123.47% N/A -35.87% Nurix Therapeutics -354.85%-53.65%-38.59% Which has more risk and volatility, ALVO or NRIX? Alvotech has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Does the media refer more to ALVO or NRIX? In the previous week, Nurix Therapeutics had 1 more articles in the media than Alvotech. MarketBeat recorded 15 mentions for Nurix Therapeutics and 14 mentions for Alvotech. Nurix Therapeutics' average media sentiment score of 1.30 beat Alvotech's score of 0.53 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ALVO or NRIX? Nurix Therapeutics has lower revenue, but higher earnings than Alvotech. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$585.60M5.23-$551.73M$0.3727.46Nurix Therapeutics$56.42M13.22-$193.57M-$2.80-3.49 Do analysts recommend ALVO or NRIX? Alvotech currently has a consensus target price of $18.00, indicating a potential upside of 77.17%. Nurix Therapeutics has a consensus target price of $30.44, indicating a potential upside of 211.29%. Given Nurix Therapeutics' higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.84 Does the MarketBeat Community prefer ALVO or NRIX? Nurix Therapeutics received 79 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 78.90% of users gave Nurix Therapeutics an outperform vote while only 50.00% of users gave Alvotech an outperform vote. CompanyUnderperformOutperformAlvotechOutperform Votes750.00% Underperform Votes750.00% Nurix TherapeuticsOutperform Votes8678.90% Underperform Votes2321.10% SummaryNurix Therapeutics beats Alvotech on 10 of the 16 factors compared between the two stocks. Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$745.59M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-3.388.9226.8419.71Price / Sales13.22253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book1.316.466.794.50Net Income-$193.57M$143.98M$3.23B$248.18M7 Day Performance3.38%2.03%1.53%0.20%1 Month Performance-14.66%4.11%10.05%12.37%1 Year Performance-39.29%-2.87%16.71%7.04% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics2.4113 of 5 stars$9.78-3.6%$30.44+211.3%-38.6%$745.59M$56.42M-3.38300News CoveragePositive NewsGap UpALVOAlvotech1.752 of 5 stars$10.25+5.9%$18.00+75.6%-27.1%$3.09B$489.68M-5.544High Trading VolumeSRRKScholar Rock3.8838 of 5 stars$32.46+5.8%$42.67+31.4%+150.4%$3.08B$33.19M-13.81140Positive NewsAnalyst RevisionGap UpMRUSMerus3.2157 of 5 stars$42.41+3.7%$85.15+100.8%-1.2%$2.94B$36.13M-10.7437Analyst ForecastGap UpACADACADIA Pharmaceuticals3.2714 of 5 stars$17.52+0.5%$24.70+41.0%+43.1%$2.93B$957.80M22.46510Trending NewsAnalyst ForecastAnalyst RevisionGap UpCPRXCatalyst Pharmaceuticals4.61 of 5 stars$23.83+2.0%$32.29+35.5%+47.1%$2.91B$534.65M20.1980Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.3727 of 5 stars$45.27+5.4%$65.44+44.6%+44.5%$2.80B$207.80M17.02120News CoveragePositive NewsAnalyst ForecastMTSRMetseraN/A$26.38+10.5%$47.00+78.2%N/A$2.77BN/A0.0081XENEXenon Pharmaceuticals3.2254 of 5 stars$35.85+2.4%$56.22+56.8%-21.9%$2.75B$9.43M-12.71210Positive NewsAnalyst DowngradeHigh Trading VolumeMLTXMoonLake Immunotherapeutics3.2841 of 5 stars$40.18+4.4%$80.50+100.3%-1.3%$2.57BN/A-31.152Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies ALVO Alternatives SRRK Alternatives MRUS Alternatives ACAD Alternatives CPRX Alternatives MOR Alternatives PTGX Alternatives MTSR Alternatives XENE Alternatives MLTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRIX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRIX Stock Free NRIX Stock Alerts